Recent research indicates that metformin, a commonly used diabetes medication, may offer significant benefits for patients experiencing long COVID symptoms, including fatigue and cognitive dysfunction. The proposed mechanisms involve anti-inflammatory effects and support for viral clearance. Meanwhile, emerging data highlights the importance of lowering lipoprotein(a), or Lp(a), as a strategic approach to reducing cardiovascular disease risk, with novel therapies showing promising results in clinical trials. These findings underscore evolving treatment landscapes in post-viral conditions and preventive cardiology.

Source link

Exit mobile version